Libtayo

Sanofi’s immunotherapy Libtayo gets FDA not in first line lung cancer

by Nile
February 23, 2021

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer, in non-small cell lung cancer patients whose tumours have high PD-L1 expression brings the drug into competition with… Read More »Sanofi’s immunotherapy Libtayo gets FDA not in first line lung cancer

Regeneron pairs with BioNTech on melanoma immunotherapy

by Nile
August 3, 2020

Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech in melanoma in people who have failed treatment with other checkpoint inhibitors. The two companies will carry out a phase 2 trial of Libtayo (cemiplimab) alongside BioNTech’s… Read More »Regeneron pairs with BioNTech on melanoma immunotherapy